Chong Kun Dang Pharmaceutical Corporation

Ckd Bio Corp.

Byoung-Taek Choi

Kyung-Hwan Kim

Tae-Won Kang

Byoung Kook Kim

Sung-Ho Hwang

Nak Kyu Sung

Yong-Rack Choi

Chung-II Hong

Gang-Sun Choi

Jang Woo Park

Disclosed is a method for purifying teicoplanin Acomprising: (i) a primary pre-purification step of purifying a filtrate of fermentation broth of a strain using a synthetic adsorbent; (ii) a secondary pre-purification step of purifying the primary pre-purification solution using a cation exchange resin having a high cross-linkage, a catalytic resin or a chelate resin; (iii) a final purification step of purifying the secondary pre-purification solution using a reversed phase resin; and (iv) a powder-forming step. According to the present invention, it is possible to obtain teicoplanin Awith a higher purity through a relatively simple process without using an excessive amount of an organic solvent.

[object Object]

A nystatin-resistant mutant microorganism belonging to genus is provided for preparing triol heptanoic acid, a precursor of 3-hydroxy-3-methylglutaryl-CoA reductase inhibitor. A mutant CLS247-13, KCTC 0673 BP is prepared by treating CLS216-7, KCTC 0359 BP with ultraviolet ray or chemical mutagens. The mutant provides high productivity (at least 11.5 g/L, 95/6% of the total product) of triol heptanoic acid, while reducing (less than 0.53 g/L, 4.4% of total product) productivity of triol heptanoic acid analogues. Since the nystatin-resistant mutant strain CLS347-13 has a capability of producing triol heptanioc acid with a high yield in a short period of culture time compared with known triol heptanoic acid producing strains, it can be widely used in industrial applications.

Nystatin-resistant Aspergillus terreus CLS 247-13, KCTC 0673BP for preparing triol heptanoic acid employing the same

Growing community of inventors

Seoul, South Korea

Byoung-Taek Choi